Recent Advances in Multiple Myeloma: Applying Real-World Evidence to Clinical Practice

Dr Luciano Costa provides an overview of the currently available treatment options for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Rafael Fonseca, MD, describes key data from the MAIA and SWOG 0777 studies investigating triplet regimens in multiple myeloma treatment, and how the results compare.

A key opinion leader explains whether doublet regimens still have a place in transplant-ineligible multiple myeloma treatment.

Dr Rafael Fonesca illustrates how he selects therapies for patients with transplant-ineligible multiple myeloma based on real-world evidence.

Luciano Costa, MD, PhD, discusses his maintenance therapy strategies for patients with transplant-ineligible multiple myeloma.

An expert describes how he determines treatment duration and discontinuation for transplant-ineligible multiple myeloma in his clinical practice.

A look at some of the unmet needs in transplant-ineligible multiple myeloma, particularly within the unfit patient population.

Drs Costa and Fonesca close out their discussion by highlighting the endemic racial disparities in multiple myeloma treatment.

Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.

An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.

Ajay Nooka, MD, explains how he selects treatment regimens for patients with newly diagnosed transplant-eligible multiple myeloma in his clinical practice.

An oncologist muses on the potential of real-world data in evaluating the use of a quadruplet regimen for newly diagnosed transplant-eligible multiple myeloma.

Drs Nooka and Pianko discuss how they measure a successful treatment response in patients with transplant-eligible multiple myeloma after induction therapy.

Following the 2022 American Society of Clinical Oncology Annual Meeting, experts in multiple myeloma discuss real-world evidence as it relates to the present-day treatment of patients.

Dr Matthew James Pianko details how he determines treatment duration and discontinuation for transplant-eligible multiple myeloma.

Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.

A look at some of the unmet needs in transplant-eligible multiple myeloma, particularly within the high-risk patient population.

Ajay Nooka, MD, and Matthew James Pianko, MD, discuss how they risk stratify patients with transplant-eligible multiple myeloma and the corresponding treatment approaches.